NYSE:AIM AIM ImmunoTech (AIM) Stock Price, News & Analysis → Elon Musk’s Final Masterpiece: “X-9840” (From Paradigm Press) (Ad) Free AIM Stock Alerts $0.41 -0.04 (-8.95%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$0.40▼$0.4650-Day Range$0.35▼$0.6152-Week Range$0.31▼$0.75Volume493,316 shsAverage Volume235,171 shsMarket Capitalization$20.96 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrends Get AIM ImmunoTech alerts: Email Address Ad Porter & CompanyTrump’s arrest is phase oneIn this new documentary, you’ll discover the truth about Trump’s criminal conviction, who’s really pulling the puppet strings, and why this is just phase one in their dark plan to reshape America. It’s not just about blocking Trump’s re-election… To get all the details, go here now. About AIM ImmunoTech Stock (NYSE:AIM)AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.Read More AIM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AIM Stock News HeadlinesMay 8, 2024 | insidertrades.comAIM ImmunoTech Inc. (NYSE:AIM) COO Peter W. Rodino III Buys 30,865 SharesJune 3, 2024 | globenewswire.comAIM ImmunoTech to Participate in the Virtual Investor Lunch Break SeriesMay 31, 2024 | globenewswire.comAIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct OfferingMay 20, 2024 | globenewswire.comAIM ImmunoTech to Participate in Two Upcoming Investor ConferencesMay 17, 2024 | markets.businessinsider.comBuy Rating Affirmed: AIM ImmunoTech’s Ampligen Shows Promising Oncology Pipeline ProgressMay 17, 2024 | finance.yahoo.comQ1 2024 AIM ImmunoTech Inc Earnings CallMay 17, 2024 | msn.comAIM ImmunoTech Inc. (AMEX:AIM) Q1 2024 Earnings Call TranscriptMay 16, 2024 | finanznachrichten.deAIM ImmunoTech Inc.: AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 16, 2024 | investorplace.comAIM Stock Earnings: AIM ImmunoTech Misses EPS for Q1 2024May 16, 2024 | globenewswire.comAIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 15, 2024 | msn.comAIM ImmunoTech Q1 2024 Earnings PreviewMay 9, 2024 | globenewswire.comAIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and WebcastMay 6, 2024 | finanznachrichten.deAIM ImmunoTech Inc.: AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®May 6, 2024 | baystreet.caAIM Completes Ampligen TurnoutMay 6, 2024 | globenewswire.comAIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®April 29, 2024 | globenewswire.comAIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic CancerApril 25, 2024 | globenewswire.comAIM ImmunoTech Announces Release of the Next CEO Corner SegmentApril 15, 2024 | finanznachrichten.deAIM ImmunoTech Inc.: AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID ProgramsApril 15, 2024 | globenewswire.comAIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID ProgramsApril 11, 2024 | globenewswire.comAIM ImmunoTech Announces Release of the Next CEO Corner SegmentApril 10, 2024 | markets.businessinsider.comAim ImmunoTech Announces Positive Data From Ampligen Study In Combination With PembrolizumabApril 10, 2024 | globenewswire.comAIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian CancerApril 5, 2024 | ca.news.yahoo.comNearly 600 cars recovered in sweeping auto theft crackdown in Ontario, Quebec: policeApril 4, 2024 | investing.comEarnings call: AIM ImmunoTech optimistic on Ampligen's future in oncologyApril 3, 2024 | insidermonkey.comAIM ImmunoTech Inc. (AMEX:AIM) Q4 2023 Earnings Call TranscriptSee More Headlines Receive AIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AIM ImmunoTech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/16/2024Today6/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNYSE:AIM CUSIPN/A CIK946644 Webaimimmuno.com Phone(352) 448-7797Fax215-988-1739Employees26Year Founded1990Profitability EPS (Most Recent Fiscal Year)($0.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,960,000.00 Net Margins-16,123.32% Pretax Margin-16,123.32% Return on Equity-191.38% Return on Assets-128.26% Debt Debt-to-Equity Ratio0.23 Current Ratio1.14 Quick Ratio1.14 Sales & Book Value Annual Sales$200,000.00 Price / Sales104.80 Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book2.04Miscellaneous Outstanding Shares51,500,000Free Float51,486,000Market Cap$20.96 million OptionableNot Optionable Beta-0.36 Social Links These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Thomas K. Equels Esq. (Age 71)J.D., M.S., Executive Vice Chairman, CEO & President Comp: $953.19kMr. Robert Dickey IV (Age 68)M.B.A., Chief Financial Officer Comp: $64.48kMr. Peter W. Rodino III (Age 73)Esq., J.D., COO, Executive Director of Governmental Relations, General Counsel & Secretary Comp: $484.94kAnn Marie E. CoverlyDirector of Administration & Human Resources and Deputy Investor Relations CoordinatorDr. Carol A. Smith (Age 73)Chief Manufacturing Officer & Deputy Chief Scientific Officer Comp: $170.77kDr. Christopher McAleer Ph.D.Scientific OfficerDr. Ralph Christopher Cavalli Ph.D. (Age 66)Vice President of QC & Manufacturing Comp: $234.79kMore ExecutivesKey CompetitorsJATT AcquisitionNYSE:JATTBioAtlaNASDAQ:BCABPassage BioNASDAQ:PASGGritstone bioNASDAQ:GRTSCognition TherapeuticsNASDAQ:CGTXView All CompetitorsInsidersThomas K EquelsBought 61,729 shares on 5/6/2024Total: $25,308.89 ($0.41/share)Peter W Rodino IIIBought 30,865 shares on 5/6/2024Total: $12,654.65 ($0.41/share)Nancy BryanBought 38,462 shares on 3/21/2024Total: $15,000.18 ($0.39/share)Thomas K EquelsBought 75,758 shares on 3/15/2024Total: $25,000.14 ($0.33/share)Stewart AppelrouthBought 90,910 shares on 3/15/2024Total: $30,000.30 ($0.33/share)View All Insider Transactions AIM Stock Analysis - Frequently Asked Questions How have AIM shares performed in 2024? AIM ImmunoTech's stock was trading at $0.4399 at the beginning of 2024. Since then, AIM stock has decreased by 7.5% and is now trading at $0.4070. View the best growth stocks for 2024 here. How were AIM ImmunoTech's earnings last quarter? AIM ImmunoTech Inc. (NYSE:AIM) announced its quarterly earnings results on Thursday, May, 16th. The company reported ($0.12) earnings per share for the quarter. The firm earned $0.04 million during the quarter. AIM ImmunoTech had a negative net margin of 16,123.32% and a negative trailing twelve-month return on equity of 191.38%. What other stocks do shareholders of AIM ImmunoTech own? Based on aggregate information from My MarketBeat watchlists, some companies that other AIM ImmunoTech investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), iBio (IBIO), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), VBI Vaccines (VBIV), T2 Biosystems (TTOO), Gilead Sciences (GILD), Dynavax Technologies (DVAX) and SCYNEXIS (SCYX). How do I buy shares of AIM ImmunoTech? Shares of AIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:AIM) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AIM ImmunoTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AIM ImmunoTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.